Lenz Therapeutics, Inc. (LENZ)
NASDAQ:LENZ
Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$10.18
-$0.43(-1.58%)
At close: 4:00 PM EST
$10.18
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$5.84 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)750.05K
Market Cap
$192.83M
Enterprise Value$174.25M
Total Cash (Recent Filing)$258.38M
Total Debt (Recent Filing)$673.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 19, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding31,354,395
10 Day Avg. Volume528,722
30 Day Avg. Volume750,055
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue8.30
Enterprise Value/Gross Profit9.11
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$32.20Price Target Upside216.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.93
Revenue Forecast (FY)$19.04M
Bulls Say, Bears Say
Bulls Say
High Product Gross MarginsLENZ’s unit economics show durable product-level profitability potential: net revenue per monthly pack ~ $67, ~ $60 net cash per unit after distribution, and management targets ~90% direct gross margin. These economics support scalable margins as volume grows and lower variable cost risk long-term.
Strong Cash Position, Minimal DebtA sizable cash balance and negligible debt provide runway to fund commercialization and operational scaling over the next several quarters without immediate refinancing. Low leverage reduces solvency risk and gives management flexibility to invest in field expansion or partnerships.
Early Commercial Traction And Prescriber BaseEarly prescribing scale and above‑peer productivity indicate meaningful market interest and initial adoption momentum. A large and repeat prescriber base plus improving e-pharmacy refill behavior suggest the product can build durable utilization as cohorts mature and field efforts reduce friction.
Bears Say
Substantial Cash Burn And Negative FCFPersistent negative operating and free cash flows mean the company depends on external capital to sustain its launch. Continued cash burn at current launch intensity will erode runway absent material revenue scale or cost reductions, increasing financing and execution risk over the medium term.
Elevated SG&A And Operating LossesHigh ongoing SG&A driven by DTC and field investments creates a long path to breakeven until revenue scales. Sustained operating losses pressure cash and require effective commercialization execution to convert awareness into durable sales and justify continued marketing spend.
R&D Reduced To Zero Limits Pipeline OptionalityShifting R&D to near-zero preserves capital for launch but removes internal development optionality for follow-on indications or next-generation products. This narrows long-term growth levers to commercial success, partnerships, or acquisitions, increasing strategic dependence on the current product.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $5.84 and its highest was $50.40 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $192.83M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 57 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.048 by -$0.272.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -1.07.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 31,354,395 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.048. Following the earnings report the stock price went down -20.821%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (216.31% Upside)
$32.20 (216.31% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $365.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.52%
12-Months-Change
Fundamentals
Return on Equity
-46.82%
Trailing 12-Months
Asset Growth
35.42%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging early commercial and clinical signals against clear near-term execution and financial challenges. Highlights include meaningful prescription growth (25k prescriptions, +19% QoQ), a large and growing prescriber base (10k+ prescribers), improving e-pharmacy refill patterns (two-thirds three-month packs), solid unit economics (≈$67 net per pack, ≈$60 net cash per unit), favorable early safety readouts, and a strong cash position (~$258M). Lowlights center on slower-than-expected new patient adoption, elevated SG&A and operating losses (Q1 SG&A $45M, net loss $41.5M), one-time cost-of-sales charges, and remaining uncertainty around durable refill dynamics until cohorts mature. Management outlined concrete commercialization actions (field messaging, DTC optimization, direct-to-practice selling, manufacturing improvements) intended to address adoption friction, but the launch remains early and will require demonstrated momentum in upcoming quarters.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$32.20
▲(216.31% Upside)
Technical Analysis
Ownership Overview
15.24% Insiders
16.64% Mutual Funds
50.72% Other Institutional Investors
9.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---